Welcome to our dedicated page for AC Immune SA news (Ticker: ACIU), a resource for investors and traders seeking the latest updates and insights on AC Immune SA stock.
AC Immune SA develops precision therapeutics and diagnostics for neurodegenerative diseases driven by misfolded proteins. The clinical-stage biopharmaceutical company uses its SupraAntigen® and Morphomer® platforms to advance active immunotherapies, small molecules, antibodies, vaccines and diagnostic programs for Alzheimer’s disease, Parkinson’s disease and NeuroOrphan indications.
Company news commonly covers clinical updates for ACI-24 in the ABATE Alzheimer’s disease study, ACI-7104.056 in the VacSYn Parkinson’s disease trial, ACI-19764 as an NLRP3 inflammasome inhibitor, and Tau Morphomer® small-molecule programs. Updates also include collaboration activity with global pharmaceutical partners, milestone payments, symposium presentations, financial results and cash runway disclosures.
AC Immune announced promising Phase 1b results for the anti-Abeta vaccine ACI-24 in adults with Down syndrome, correlating immune response with target engagement. The study found ACI-24 to be safe, with no serious adverse events reported. Additionally, the administration of ACI-24 resulted in increased plasma Abeta levels. The company plans further development of ACI-24 and aims to shift towards earlier treatment of Alzheimer’s disease (AD). ACI-12589, a diagnostic for Parkinson’s disease, is also being presented, with further advancements expected in the pipeline.
AC Immune (NASDAQ: ACIU) announces the acquisition of Affiris' portfolio, including the clinically-validated active vaccine candidate for Parkinson's disease, PD01, in an all-stock transaction valued at USD 58.7 million. This acquisition, supplemented by a USD 25 million private placement led by Athos Service GmbH, enhances AC Immune's cash position and accelerates therapeutic development. AC Immune plans to launch a Phase 2 study of the vaccine targeting alpha-synuclein in Parkinson’s patients, combining their expertise in vaccine development with Affiris' innovative technology.
AC Immune SA (NASDAQ: ACIU) held its Annual General Meeting, where shareholders re-elected the Board of Directors, including Douglas Williams as Chairman. The company remains focused on advancing its Alzheimer’s disease vaccine programs despite the challenges posed by COVID-19. These vaccines target key proteins related to the disease, positioning AC Immune as a potential leader in the field. All AGM resolutions were approved, and the meeting complied with COVID-19 regulations.
AC Immune SA (NASDAQ: ACIU) recently reported significant developments regarding its vaccine candidate, ACI-24, for Alzheimer's disease. The Phase 2 interim analysis confirmed a strong safety profile without any CNS inflammation or adverse events. Notably, non-human primate studies showed that the optimized ACI-24 formulation generates a robust antibody response against neurotoxic pyroglutamate Abeta, surpassing earlier formulations. The company plans to file an Investigational New Drug (IND) application by the end of 2021 and aims to enter Phase 2 trials for Down syndrome-related Alzheimer's as early as 2022/23.
AC Immune SA (NASDAQ: ACIU) announced its participation in the UBS Global Healthcare Virtual Conference on May 26, 2021, and the Jefferies Virtual Healthcare Conference from June 2-4, 2021. CEO Prof. Andrea Pfeifer will present the company’s strategy and Alzheimer’s disease vaccine programs targeting phospho-Tau and Abeta. Webcasts of the events will be available on AC Immune’s website. The company focuses on precision medicine for neurodegenerative diseases, holding a diversified pipeline with six clinical trials ongoing.
AC Immune (NASDAQ: ACIU) announced the expansion of its Phase 1b/2a clinical trial of the ACI-35.030 vaccine for Alzheimer's disease, following encouraging interim results. Vaccination at the second highest dose cohort will proceed, while the highest dose group continues to be evaluated, with initial results expected in Q4 2021. The trial aims to assess safety, tolerability, and immunogenicity of the vaccine candidates ACI-35.030 and JACI-35.054, both targeting phosphorylated Tau proteins. Encouraging data reported includes a 100% antibody response in early Alzheimer’s patients.
AC Immune SA (NASDAQ: ACIU) reported potent interim results for its anti-pTau Alzheimer’s vaccine in a Phase 1b/2a study and initiated a first-in-human study for a new alpha-synuclein PET diagnostic.
The company maintains a robust cash position of CHF 216.1 million, ensuring funding through at least Q1 2024. However, it recorded a net loss of CHF 16.7 million for Q1 2021, a significant increase from CHF 7.7 million in the previous year. The decrease in contract revenues by CHF 12.3 million mainly contributed to this loss, highlighting challenges in generating income.
AC Immune SA (NASDAQ: ACIU) has appointed Dr. Alan Colowick to its Board of Directors, enhancing its leadership in precision medicine for neurodegenerative diseases. Dr. Colowick brings over 20 years of experience in biotech, having served in executive roles at notable companies such as Celgene and Amgen, and as a Partner at Sofinnova Investments. His expertise is expected to strengthen AC Immune's pipeline, which features nine therapeutic and three diagnostic candidates, with six currently undergoing clinical trials. The appointment is seen as a pivotal move for the company's growth and strategic development.
AC Immune SA (NASDAQ: ACIU) hosted an investor webinar on March 31, 2021, highlighting its innovative Morphomer™ technology platform aimed at developing therapeutics and diagnostics for neurodegenerative diseases. CEO Prof. Andrea Pfeifer emphasized the platform's ability to create first-in-class candidates targeting key proteins like Tau and TDP-43. Notable financial achievements include over CHF 174 million from strategic partnerships. The webinar also showcased advancements in clinical validation of Morphomer candidates, including the Phase 1 study success of candidate ACI-3024.
AC Immune, a clinical-stage biopharmaceutical company, will host a corporate update webinar on March 31, 2021, from 10:00 AM to 11:30 AM ET. The focus will be on the company’s innovative Morphomer™ technology for developing targeted therapies for neurodegenerative diseases. The current pipeline includes two clinical-stage diagnostic candidates and one therapeutic candidate that has completed Phase 1. Key speakers will include CEO Andrea Pfeifer and CSO Marie Kosco-Vilbois, among others. This event will include an interactive Q&A session with the audience.